Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 139, Issue 3, Pages 501-509Publisher
WILEY
DOI: 10.1002/ijc.30051
Keywords
arginine deprivation; recombinant human arginase; arginine deiminase
Categories
Funding
- MRC [MC_PC_14123] Funding Source: UKRI
- Medical Research Council [MC_PC_14123] Funding Source: Medline
- Cancer Research UK [22590, 17973] Funding Source: researchfish
Ask authors/readers for more resources
Renewed interest in the use of therapeutic enzymes combined with an improved knowledge of cancer cell metabolism, has led to the translation of several arginine depletion strategies into early phase clinical trials. Arginine auxotrophic tumors are reliant on extracellular arginine, due to the downregulation of arginosuccinate synthetase or ornithine transcarbamylase-key enzymes for intracellular arginine recycling. Engineered arginine catabolic enzymes such as recombinant human arginase (rhArg1- PEG) and arginine deiminase (ADI-PEG) have demonstrated cytotoxicity against arginine auxotrophic tumors. In this review, we discuss the molecular events triggered by extracellular arginine depletion that contribute to tumor cell death.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available